Clinical Trial Update: Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia [NA]

View source ↗

Summary

ClinicalTrials.gov update on a completed trial evaluating CPX-351 (liposomal cytarabine-daunorubicin) for untreated myelodysplastic syndrome or acute myeloid le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• CPX-351 (Vyxeos) (CPX-351)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | NA | Status: COMPLETED | Results posted: 2018-05-25